Objective-Sirolimus-eluting stent therapy has achieved considerable success in overcoming coronary artery restenosis.
P ercutaneous coronary intervention has been established as a major treatment of coronary artery diseases worldwide. 1 Recently, the application of drug-eluting stent technology has been shown to improve clinical outcomes after treatment compared with bare metal stents. Clinically approved drug-eluting stents such as Cypher (Cordis) and Taxus (Boston Scientific), which deliver sirolimus and paclitaxel, respectively, have been shown to substantially reduce the rates of clinical restenosis across a broad range of lesions and patient subsets. 2, 3 The widespread use of these drugs sparked considerable interest in researchers to further dissect and elucidate their mechanisms of action within laboratory settings. 4, 5 It has been demonstrated that sirolimus (or rapamycin) has a predominant role in reducing intimal hyperplasia by inhibiting smooth muscle cell (SMC) proliferation, growth factor-stimulated DNA synthesis, 6, 7 and matrix protein deposition. 2 Although sirolimus-eluting stent therapy has been widely adopted in clinical practice, a panel of reports indicates the reoccurrence of restenosis after the treatment in a considerable number of patients. [8] [9] [10] To date, it remains unclear as to how and why restenosis still persists in a substantial number of patients, despite the established antiproliferative roles of sirolimus within stents.
In recent years, the identification of stem/progenitor cells that reside in various compartments of the vessel wall captured the interest of many investigators to evaluate their roles in vascular diseases. [11] [12] [13] [14] [15] Previous studies from our laboratory indicated that the vascular adventitia harbored a population of cells that were positive for stem/progenitor markers such as stem cell antigen-1 (Sca-1), c-kit, and CD34. 11 More recently, October 2013 using a decellularized vessel mouse model, Tsai et al 16 demonstrated a marked accumulation of stem/progenitor cells within neointimal lesions. Interestingly, stem/progenitor (vascular progenitor) cells displayed the potential to differentiate into both endothelial cells (EC) and SMCs under specific stimulus. 16, 17 Furthermore, accumulating evidence also suggests a migratory capacity of vascular progenitor cells, whereby they migrate from one vessel wall compartment to another (ie, from adventitia to intima) 11, 17 in response to molecular effectors such as stromal-derived factor 1 (SDF-1) and vascular endothelial growth factor. 18 Therefore, although traditionally perceived to be quiescent, 19 we hypothesize that vascular progenitors can contribute to restenosis in response to sirolimus via their deployment and vascular lineage differentiation. The present study aims to address the roles of sirolimus on vascular progenitor cell chemotaxis and differentiation using both in vitro and ex vivo bioreactor systems. The potential effects of sirolimus on this specific cell population may represent key factors that contribute to the recurrence of restenosis after sirolimus drug-eluting stent placement, thus opening crucial avenues that can be applied to increase the efficacy of stenting treatment.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Sirolimus Can Induce Vascular Progenitor Cell Chemotaxis
We first performed an in vitro scratch-wound assay to investigate the chemotactic behavior of vascular progenitors that were Sca-1+Lin− ( Figure I in the online-only Data Supplement) in response to sirolimus. We found that sirolimus treatment significantly induced vascular progenitor cell migration in a dose-dependent manner ( Figure 1A and 1B). We confirmed the observations using a 8-μm transwell system, whereby cells that migrate in response to sirolimus (1 μg/mL) were quantified after 1% crystal violet staining subsequent to an overnight incubation ( Figure 1C ). In these transwell experiments, either serum-free media or dimethyl sulfoxide was used as controls. Consistent with the results from the scratch assays, we found that sirolimus induced marked chemotaxis of vascular progenitor cells ( Figure 1C and 1D). Taken together, data demonstrated that sirolimus is an inducer of vascular progenitor chemotaxis, particularly at high doses such as 1 μg/mL. Indeed, sirolimus has been documented to be effective over a range of relatively high doses in animal models (ie, 18 μg/18-mm stent). 2 Therefore, subsequent experiments using vascular progenitor cells were performed with 1 μg/mL of sirolimus.
Sirolimus Induces Vascular Progenitor Chemotaxis via CXCR4 Activation
We next aimed to elucidate the mechanisms that drive the sirolimus-mediated chemotactic induction of vascular progenitor cells. It has been established that chemokine receptors and their corresponding ligands play critical roles in regulating the mobilization of many cell types, [20] [21] [22] depending on the appropriate pathophysiological conditions that are present. Therefore, we evaluated the potential changes of a panel of chemokine receptors after treatment with sirolimus. Gene expression of the chemokine receptors was represented as fold change based on control cells that were cultured in normal culture medium. We observed that sirolimus markedly induced the expression of CCR2, CCR3, CXCR2, CXCR4-6, CX3CR1, and XCR1; the upregulation of CCR9 was significant, albeit low ( Figure 2A ). Interestingly, it was also shown that CXCR4 was the highest upregulated gene in response to sirolimus (increment of 11.087±5.81 folds compared with control). The induction was subsequently confirmed at protein level using flow cytometry, whereby treatment with sirolimus resulted in a homogeneous increase in CXCR4 expression (mean fluorescence intensity=4.72±0.79; Figure 2B ).
To test whether CXCR4 is involved in the sirolimusmediated induction of vascular progenitor chemotaxis, we performed a scratch-wound assay in the presence of CXCR4 antagonists, that is, AMD3100 or CXCR4 Antagonist II. We observed that the presence of either antagonist significantly attenuated sirolimus-mediated induction of vascular progenitor migration ( Figure 2C ). Consistently, subsequent experiments using the transwell system showed a significant abrogation of vascular progenitor chemotaxis in response to sirolimus when the cells were pretreated either with AMD3100 or with CXCR4 Antagonist II ( Figure 2D ). The results were also confirmed using a CXCR4 small interfering RNA ( Figure II in the online-only Data Supplement). Furthermore, we showed that sirolimus-treated vascular progenitors have increased chemotactic responses toward SDF-1, which is known to be a specific ligand of CXCR4 ( Figure 2E ). It is, however, noteworthy that although exogenous SDF-1 could induce vascular progenitor chemotaxis, the chemokine was not involved in the sirolimus-mediated effects because ELISA assays did not indicate detectable levels of SDF-1 in conditioned medium of sirolimus-treated vascular progenitor cells ( Figure IIIA in the online-only Data Supplement). In consideration that CCR2, CCR3, and CXCR2 were also significantly upregulated in response to sirolimus (Figure 2A ), we sought to confirm whether the receptors could also contribute to the chemotactic induction. Using scratch-wound assays, we demonstrated that the presence of antagonists for CCR2 (CCR2 antagonist), CCR3 (SB328437), and CXCR2 (SB225002) failed to inhibit vascular progenitor migration ( Figure IIIB and IIIC in the online-only Data Supplement). Furthermore, the presence of corresponding ligands (CCR2, monocyte chemotactic protein-1; CCR3, regulated on activation, normal T cell expressed and secreted and eotaxin; CXCR2, keratinocyte-derived chemokine) was also undetectable in conditioned medium of sirolimus-treated vascular progenitor cells ( Figure IIID in the online-only Data Supplement). Therefore, the results confirm that the respective chemokine receptors, although upregulated, were not involved in mediating the chemotactic effects of sirolimus. Our data thus far provide evidence that sirolimus can induce vascular progenitor migration through direct activation of the CXCR4 receptor.
In light of our in vitro results, we sought to confirm the chemoattractance of vascular progenitor cells toward sirolimus within a physiological environment. Therefore, we used a bioreactor system that has been previously established in our laboratory, 23 with slight modifications. In the present study, vascular progenitor cells were allowed to seed and attach onto the outer layer of a decellularized vessel graft within which culture medium containing sirolimus was infused; similar bioreactors either with normal culture medium or with culture medium containing exogenous SDF-1 were used as controls. Vascular progenitor migration from the outer to inner layers of the vessel was sequentially analyzed. Compared with culture medium-only controls, we found markedly increased number of cells that migrated Changes in migration in response to sirolimus in the presence of CXCR4 inhibitors (AMD3100, 50 μmol/L or CXCR4 Antagonist II, 50 nmol/L) were evaluated using either a (C) scratch-wound or (D) a transwell assay. E, The transwell assay was performed on vascular progenitor cells that were pretreated with sirolimus for 24 hours before migration toward either serum-free media or serum-free media containing murine recombinant stromalderived factor 1 (SDF-1; 10 ng/mL). Untreated vascular progenitor served as controls. F, Vascular progenitor cells (5×10 5 ) were seeded on the outside of previously decellularized vessels and allowed to migrate inward in response to media containing sirolimus (1000 ng/mL) inside the vessel. Complete media in the absence of sirolimus or media containing SDF-1 (10 ng/mL) were used as controls. Vessel sections were prepared for either hematoxylin and eosin (H/E; left) or immunoflourescent marker staining (right; scale bars, 50 μm). G, The total number of DAPI+ cells and (H) the percentage of stem cell antigen-1 (Sca-1)-positive cells within respective DAPI+ populations were quantified and represented as graphs. Images shown are representative of ≥3 separate grafts, whereas graphs are shown as mean±SEM of ≥3 independent experiments. *P<0.05, ***P<0.005 compared with untreated control. Antag II indicates Antagonist II; and Siro, sirolimus.
into the vessel wall ( Figure 2F ). Furthermore, we observed the formation of neointima-like lesions in sirolimus-treated groups, as visualized by hematoxylin and eosin ( Figure 2F , left, middle). Fluorescent staining with a nuclear dye, diamidino-2-phenylindole, confirmed a marked increment of vascular progenitor migration into decellularized vessels in response to sirolimus ( Figure 2G ). Consistent with our in vitro data ( Figure 2E ), SDF-1 controls were also found to induce vascular progenitor migration into the vessels, however, to a lesser extent compared with sirolimus ( Figure 2G ). Additional in vitro data demonstrated that sirolimus inhibits vascular progenitor cell proliferation that is likely to be mediated by the suppression of mammalian target of rapamycin expression 2 ( Figure IV in the online-only Data Supplement). Similarly, SDF-1 did not induce vascular progenitor proliferation ( Figure VA in the online-only Data Supplement). Taken together, our data confirm that the increase of cells within either SDF-1-infused or sirolimus-infused ex vivo vessels was indeed because of vascular progenitor cell migration and not their proliferation. Interestingly, the number of vascular progenitor cells that have migrated either into control or SDF-1 vessels consistently expressed the progenitor marker, Sca-1, whereas the majority of vascular progenitors that migrated in response to sirolimus did not express the marker ( Figure 2H ). The loss of progenitor marker expression suggests that sirolimus may also induce their differentiation into another cell type. Thus, our in vitro and ex vivo results provide evidence of the role of sirolimus in inducing vascular progenitor cell chemotaxis.
Sirolimus Induce Vascular Progenitor Differentiation Into SMCs
The loss of Sca-1 expression in vascular progenitor cells in response to sirolimus prompted us to ask the question of whether sirolimus can also induce the differentiation of the cells after their migration into decellularized vessels. Indeed, a substantial body of work has shown the capacity of these progenitors to differentiate into vascular lineages such as SMCs. 18 Furthermore, the differentiation of vascular progenitors into SMC has been shown to expedite neointima formation and atherosclerosis. 11, 16 To address the hypothesis, we stained vessel sections (same as for Figure 2F ) with SMCspecific markers (calponin and SM-22α). We found that a majority of vascular progenitors that migrated into decellularized vessels in response to sirolimus expressed both calponin and SM-22α ( Figure 3A and 3B) compared with control vessels. In contrast, a markedly low number of cells that have migrated in response to SDF-1 expressed SMC markers ( Figure 3A and 3B and Figure VB in the onlineonly Data Supplement), suggesting that SMC differentiation of vascular progenitors was specific to the effects of sirolimus. Next, we aimed to confirm the capacity of sirolimus to induce vascular progenitor-SMC in vitro. Interestingly, vascular progenitors that were treated with sirolimus indicated obvious changes in cell morphology and increased cell size compared with controls ( Figure 4C and 4D ). Furthermore, sirolimus-treated cells showed a consistent increment of contractile SMC marker expression at the mRNA level ( Figure 3E ). The results were subsequently confirmed at the protein level ( Figure 3F and 3G). Taken together, these data demonstrated that sirolimus can induce vascular progenitor cell migration and simultaneously drive their differentiation into the SMC lineage.
Sirolimus-Induced Differentiation Is Mediated by ERK1/2 Activation via EGFR Signaling
To understand the underlying mechanisms that drive vascular progenitor-SMC differentiation in response to sirolimus, we wanted to test whether the chemokine receptor was also involved in the induction of vascular progenitor-SMC differentiation. Thus, we performed real-time reverse transcription polymerase chain reaction to evaluate SMC gene expression of vascular progenitor cells that were cultured in the presence of CXCR4 antagonists (AMD3100 or CXCR4 Antagonist II) in response to sirolimus. Results showed that neither CXCR4 antagonists had significant effects on sirolimus-induced SMC gene expression ( Figure 4A and Figure VI in the online-only Data Supplement), thus indicating that although the receptor was involved in sirolimus-mediated vascular progenitor chemotaxis, it did not play a significant role in vascular progenitor-SMC differentiation. Data thus far suggest that sirolimus-mediated induction of vascular progenitor chemotaxis and their differentiation into SMC are regulated via independent signaling pathways.
The epidermal growth factor receptor (EGFR) has recently been demonstrated to mediate the prosurvival effects of sirolimus on cancer cells. 24 In the present study, we show that treatment with sirolimus resulted in a significant increment of EGFR phosphorylation ( Figure 4B ). To confirm its role in vascular progenitor-SMC differentiation, an EGFR antagonist (AG-1478) was used concomitantly with sirolimus treatment. Data showed that the upregulation of SMC expression in response to sirolimus was significantly ablated in the presence of AG-1478 ( Figure 4C and 4D and Figure VII in the online-only Data Supplement). The results were also confirmed in experiments using lentiviral short hairpin RNA for EGFR ablation ( Figure  VIII in the online-only Data Supplement). It is noteworthy that the presence of AG-1478 did not cause significant changes in the sirolimus-induced chemotaxis ( Figure IX in the online-only Data Supplement), thus confirming that the induction of vascular progenitor chemotaxis and differentiation of SMC by sirolimus are mediated by independent receptor signaling pathways.
Subsequently, we aimed to elucidate the downstream signaling mechanisms that are involved in the EGFR-mediated effects of SMC differentiation by sirolimus. In consideration that sirolimus can stimulate the extracellular signal-regulated kinase (ERK) 1/2 signaling pathway through EGFR activation, 24 we decided to test whether the activation of ERK1/2 is also involved in mediating the SMC-inductive effects of sirolimus. We found that treatment with sirolimus caused a time-dependent increase in phospho-ERK1/2 ( Figure 4E) . Concomitantly, the presence of an ERK1/2 inhibitor (PD98059) caused an abrogation of the sirolimus-induced SMC marker protein induction ( Figure 4F ). Furthermore, the inhibition of EGFR resulted in the attenuation of sirolimusmediated ERK1/2 activation ( Figure 4G and Figure VIII in the online-only Data Supplement), indicating that vascular progenitor-SMC differentiation by sirolimus is regulated by ERK1/2 activation via EGFR signaling.
Sirolimus Can Induce β-Catenin Nuclear Translocation to Activate SM-22α Promoter
Recent work by Singh et al 25 postulated a critical crosstalk between ERK1/2 and β-catenin signaling pathways that is essential to promote the differentiation of pluripotent cells. Thus, this led us to ask whether β-catenin was also involved in sirolimus-mediated vascular progenitor-SMC differentiation downstream of ERK1/2. We observed an increase in the levels of active β-catenin that showed the highest expression at 24 hours ( Figure 5A ) and was concomitant with the increase in phospho-ERK1/2 seen in Figure 4E . The role of β-catenin in mediating the effects of sirolimus was then confirmed using lentiviral short hairpin RNA knockdown of the gene in vascular progenitor cells. Figure 5B showed that the knockdown of β-catenin resulted in a marked ablation of SMC induction in response to sirolimus. Furthermore, the ablation of either EGFR (AG-1478 antagonist and EGFR short hairpin RNA) or ERK1/2 (PD98059 inhibitor) was found to inhibit the sirolimus-mediated increment of active β-catenin ( Figure 5C and 5D and Figure VIII in the online-only Data Supplement), thereby indicating that sirolimus induces vascular progenitor-SMC differentiation specifically through an EGFR/ERK1/2/β-catenin signaling cascade.
Furthermore, subsequent immunoflourescent staining showed that β-catenin was mostly expressed within the nucleus of sirolimus-treated vascular progenitor cells, which was concomitant with the induction of SMC markers, SM-22α and smooth muscle-myosin heavy chain ( Figure 5E, bottom) . In contrast, although SMC marker expression of untreated vascular progenitor cells (control) was found to be markedly lower, β-catenin expression was mainly restricted within the adherent junctions of the cells (Figure 5E, top) . Using luciferase reporter assays, we observed a significant increment of SM-22α promoter activity in response to sirolimus, which was markedly ablated in the presence of the EGFR antagonist ( Figure 5F ) or ERK1/2 inhibitor ( Figure 5G ) or in β-catenin short hairpin RNA knockdown vascular progenitor cells ( Figure 5H ). Altogether, our data provide the first evidence of the EGFR/ERK1/2/β-catenin signaling cascade that is responsible for regulating sirolimus-driven vascular progenitor-SMC differentiation.
Sirolimus Inhibits Vascular Progenitor Differentiation Into EC
In light of work that implicates the ability of vascular progenitor cells to also differentiate into the endothelial lineage, we wondered whether sirolimus-mediated differentiation of vascular progenitor cells after their migration was restricted to SMCs. To test the hypothesis, we stained vessel sections Figure 3A , with immunoflourescent markers for endothelial lineage (ie, CD144 and CD31). We observed that there was no obvious expression of the markers in both control and sirolimus-treated vessels ( Figure 6A ), suggesting that sirolimus did not induce vascular progenitor-endothelial differentiation after their migration into the vessels. It is noteworthy that the endothelial markers have been demonstrated to efficiently stain luminal cells of decellularized vessel scaffolds containing partially induced pluripotent stem cell-derived EC. 23 Concomitant in vitro data showed that sirolimus treatment did not induce significant endothelial marker expression of vascular progenitor cells ( Figure 6B ), confirming the specificity of sirolimus in driving vascular progenitor-SMC differentiation. Furthermore, subsequent results demonstrated that sirolimus treatment resulted in a significant attenuation of vascular progenitor-endothelial differentiation in response to VEGF, both at mRNA ( Figure 6C ) and protein levels ( Figure 6D ). Altogether, our data provide novel evidence that sirolimus can induce vascular progenitor chemotaxis and their specific differentiation into SMCs, and not EC, through independent receptor signaling pathways.
Discussion
Recent advances in the use of sirolimus-eluting stent have undoubtedly achieved substantial success in attenuation of the key culprit in vascular diseases-restenosis. 1,2 Despite promising outcomes, there remains an alarming increase in reported stent failures and recurrence of restenosis after stenting. Although a large body of work has been performed by many laboratories, they mostly focus on the effects of sirolimus on key cellular populations such as EC and SMCs. [4] [5] [6] As yet, the precise mechanisms that cause the persistence of restenosis in sirolimus-coated stents remain unclear. Our study provides novel and crucial evidence that sirolimus can induce both migration and SMC differentiation of vascular progenitor cells, both of which are regulated via independent signaling pathways. We think that our findings provide basic information for understanding the mechanisms that drive restenotic persistence after sirolimus-eluting stent treatment, that is, the cumulative effects of sirolimus on this population of progenitor cells.
Recently, accumulating data have revolutionized the classical view of the functional roles that vascular progenitor cells play in the vascular system. [11] [12] [13] [14] [15] Although they were predominantly understood to serve as building blocks that either protect or repair the endothelium, increasing evidence strongly implicates the major role of progenitor (or stem) cells in various cardiovascular diseases, including atherosclerosis and angioplasty-induced restenosis. 16 These cells express progenitor markers, such as Sca-1, CD34, or CD117, and have been found to localize in different compartments of the vessel, namely neointima 16 and adventitia. 11, 19 The vascular adventitia was also identified as a niche that harbors various stem/progenitor cells such as mesenchymal stem cells, hematopoietic stem cells, and germline stem cells. 19, 26, 27 Our in vitro and ex vivo data confirmed that sirolimus can act as a potent chemoattractant of neointimal-derived Sca-1+Lin− vascular progenitor cells and an inducer of their differentiation into SMCs. Furthermore, we also demonstrated that both adventitia-derived and embryonic stem cell-derived Sca-1+ progenitor cells display similar responses to sirolimus (Figures X and XI in the online-only Data Supplement). The recently identified mesoangioblast displays similarities to our vascular progenitor cells in terms of their Sca-1 cellsurface expression, self-renewal, and multipotent differentiation capacities and, therefore, may also exist as source of cells that can respond to sirolimus. 28 It is, however, noteworthy that mesangioblasts also express CD34 and fetal liver kinase-1, 28 which our Sca-1+ progenitors lack. Interestingly, we found that CD34+ vascular progenitor cells failed to migrate in response to sirolimus but displayed low levels of sirolimus-mediated SMC differentiation compared with Sca-1+ cells ( Figure XII in the online-only Data Supplement). As expected, adult mouse fibroblasts that were used as a negative control in this study did not migrate or differentiate in response to sirolimus ( Figure XIII in the online-only Data Supplement). These data suggest that the inductive effects of sirolimus on vascular progenitor migration or SMC differentiation are likely restricted to the Sca-1+ progenitors derived from a specific niche within the vessel wall. It is also plausible that sirolimus can induce the mobilization of other sources of Sca-1+ progenitor cells and guide them toward stented areas within the vessel, thus giving rise to restenosis. [29] [30] [31] Chemokine receptor signaling plays a key role in the migratory behavior and chemotaxis of many cell types. These receptors are upregulated especially in response to tissue injury or pathological conditions. [20] [21] [22] Unlike other stem cells such as MSC 32 or HSC, 33 the chemokine receptor expression profile of stem/progenitor cells within the vascular system remains poorly defined. To date, our data constitute the first indication of changes in chemokine receptor expression of vascular progenitor in response to sirolimus. We confirmed that although sirolimus could upregulate the expression of several chemokine receptors, CXCR4 remains as the sole receptor by which sirolimus directly activates vascular progenitor migration. Furthermore, the upregulation of CXCR4 results in a marked increase in vascular progenitor migration toward its respective ligand, SDF-1. Although we confirmed that the stimulation of vascular progenitor cells with sirolimus does not result in a detectable secretion of SDF-1, other cell types such as SMCs have been shown to secrete the chemokine. 29, 30 Thus, the homing of vascular progenitor cells, such as those that are located further away from the intima (ie, adventitia), toward stented areas in response to sirolimus can be augmented by SDF-1 derived from SMCs within the medial compartment. The accumulation of vascular progenitors as a result of their migration via CXCR4 formulates a reservoir of cells that serve to differentiate toward the SMC lineage, ultimately leading to restenosis.
The EGFR has been established to be essential for the support of malignant phenotypes in human cancers and plays a critical role in tumorigenesis. 24 However, its role in cardiovascular pathologies, such as atherosclerosis and neointimal hyperplasia, remains poorly understood. [34] [35] [36] Our study is the first to demonstrate that progenitor-SMC differentiation is regulated specifically through EGFR activation, which is required for subsequent downstream ERK1/2 signaling. Consistent with survival studies performed in cancer cells, we found that the activation of EGFR (phosphorylation at tyrosine 845) is a result of direct stimulation by sirolimus and is independent of additional growth factors 24 or autocrine factors such as transforming growth factor-α ( Figure XIV in the online-only Data Supplement). Furthermore, the subsequent phosphorylation and activation of EGFR are likely to be mediated by p-Src activation. 24 Studies on the Wnt/β-catenin signaling pathway have mainly focused on its role as a regulator of cellular growth and proliferation, but its role in vascular differentiation remains poorly defined. 37 Recently, Shafer et al 38 provided crucial evidence that nuclear-translocated β-catenin can directly induce the transcriptional regulation of the SM-22α promoter by binding to specific promoter sequences, thus implicating that β-catenin can play a direct role in inducing SMC expression. Indeed, our study clearly demonstrated that the phosphorylation of ERK1/2 is critical for the subsequent accumulation of active β-catenin and their translocation into the nucleus; these are required for SM-22α promoter activation and stimulation of SMC differentiation. In accordance with our data, the transforming growth factor β-1-mediated activation of ERK1/2 was demonstrated to induce nuclear translocation of β-catenin as a result of glycogen synthase kinase-3β (GSK-3β) inhibition (active GSK-3β promotes β-catenin degradation), thus leading to an increment of SM-αA expression in human lung fibroblasts. 39 Similarly, the small interfering RNA knockdown of mammalian target of rapamycin resulted in a marked downregulation of GSK-3β in cardiac myocytes, followed by the stabilization and nuclear translocation of β-catenin. 40 Although the authors also showed that mammalian target of rapamycin inhibition using rapamycin (sirolimus) failed to elicit the same effects, 40 translocation could be because of the low concentration of rapamycin that was used (50 ng/mL). Indeed, we found that sirolimus-mediated Sca-1+ vascular progenitor-SMC differentiation was almost undetectable at concentrations of ≤100 ng/mL ( Figure XV in the online-only Data Supplement). Taken together, we show that sirolimus-induced SMC differentiation is directly regulated through EGFR signaling via ERK1/2 activation and accumulation of active β-catenin, which is likely to be mediated by the inhibition of GSK-3β. Subsequent nuclear translocation of β-catenin leads to the activation of the SM-22α promoter by binding to a specific promoter region, thus promoting SMC differentiation. Furthermore, the addition of recombinant Dickkopf-related protein 1 (a negative regulator of Wnt signaling) failed to abrogate sirolimus-mediated SMC differentiation, thus indicating that the activation of EGFR-mitogen-activated protein/ERK-β-catenin signaling pathway is independent of canonical Wnt/LRP receptor signaling pathways ( Figure  XVI in the online-only Data Supplement). Vascular progenitor cells have previously been shown to be capable of differentiating into both SMC and EC under specific stimulus. 16, 41 The differentiation of endothelial progenitor cells into mature, functional EC is required for the repair of the damaged vessel after endovascular injuries, which include postinterventional procedures. 42 The present study showed that sirolimus can drive the lineage commitment of vascular progenitor cells predominantly into the SMC lineage, while suppressing their ability to form EC. Furthermore, sirolimus has also been found to inhibit endothelial progenitor adhesion, migration, and nitric oxide production under shear stress conditions. 3 The attenuation of vascular progenitor-endothelial differentiation and lack of functional endothelium in response to sirolimus can lead to the suppression of wound healing that is also likely to contribute to the reoccurrence of restenosis after sirolimuscoated stenting.
Data from our study postulate an unprecedented role of vascular progenitor cells as major contributors of restenosis via their migration and differentiation into SMC in response to sirolimus. Hence, although the use of sirolimus in stents remains vital to suppress SMC proliferation, the combination of additional pharmacological drugs and specific inhibitors that target vascular progenitor cellular migration and suppress vascular progenitor-SMC differentiation is likely to improve the effects of the drug-eluting stent treatment. Hamesch et al 43 demonstrated that the administration of the CXCR4 antagonist (POL5551) in apolipoprotein E-deficient mice after a mechanical carotid injury resulted in a marked reduction of neointima formation without impairment of re-endothelialization. Our findings that ERK1/2 and EGFR inhibition causes the attenuation of vascular progenitor-SMC differentiation also seem to be attractive candidates. There is evidence that pharmacological inhibition of GSK-3β (AR-A014418; Calbiochem) resulted in a significant rescue of the re-endothelialization capacity of endothelial progenitors and reduced neointima formation after rapamycin-associated stenting. 44 Because we demonstrated that the activation and nuclear translocation of β-catenin are required for vascular progenitor-SMC differentiation, it is tempting to hypothesize that the regulation of downstream Wnt signaling molecules by sirolimus may play a role in controlling the lineage differentiation of vascular progenitor cells. Thus, further research is warranted to identify the specific mechanisms by which sirolimus suppresses endothelial differentiation, in which case stents can be appropriately coated with factors that can also promote endothelium repair and sustain endothelial function.
In summary, the present study provides both in vitro and ex vivo evidence that adult vascular progenitor cells are a cell source that can actively migrate and differentiate specifically toward the SMC lineage in response to sirolimus. Concomitantly, we demonstrated that vascular progenitor migration is mediated directly via CXCR4 activation, whereas the EGFR/ERK1/2/β-catenin signaling pathway is required to drive vascular progenitor-SMC differentiation. Both receptor-activated signaling pathways are independent. In light of the presented data, a follow-up of robust in vivo experiments is still required to confirm the role of Sca-1+ vascular progenitor cells within animal models of sirolimus-eluting stents. In addition, further investigation would be needed to confirm whether our findings could be translated to the stenting condition in patients. Together, these results may provide crucial answers as to why restenosis persists after sirolimus-eluting stent treatment that may be fundamental for developing novel therapeutic approaches that can improve the efficacy and long-term safety of patients undergoing vascular stenting procedures.
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